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Abstract
Background: Diabetes mellitus brings an increased risk for cardiovascular complications and patients profit from
prevention. This prevention also suits the general population. The question arises what is a better strategy: target
the general population or diabetes patients.
Methods: A mathematical programming model was developed to calculate optimal allocations for the Dutch
population of the following interventions: smoking cessation support, diet and exercise to reduce overweight, statins,
and medication to reduce blood pressure. Outcomes were total lifetime health care costs and QALYs. Budget sizes
were varied and the division of resources between the general population and diabetes patients was assessed.
Results: Full implementation of all interventions resulted in a gain of 560,000 QALY at a cost of €640 per capita,
about €12,900 per QALY on average. The large majority of these QALY gains could be obtained at incremental
costs below €20,000 per QALY. Low or high budgets (below €9 or above €100 per capita) were predominantly
spent in the general population. Moderate budgets were mostly spent in diabetes patients.
Conclusions: Major health gains can be realized efficiently by offering prevention to both the general and the
diabetic population. However, a priori setting a specific distribution of resources is suboptimal. Resource allocation
models allow accounting for capacity constraints and program size in addition to efficiency.
Background
ifestyle risk factors, especially a high body weight, play
an important role in the development of diabetes [1,2].
Due to ongoing ageing and unfavourable trends in life-
style in the population diabetes prevalence is increasing
rapidly [3,4]. Diabetes patients risk a number of micro
and macro vascular complications, with 40 to 56% of
the patients suffering from one or more of these.
Macrovascular complications are responsible for the
majority of complication related use of health care and
consist of cardiovascular disease and stroke [5]. Preven-
tion aiming at the reduction of cardiovascular risks has
therefore the potential to reduce the burden of diabetes
[6,7] and is included in current diabetes guidelines.
However, given the prevalence of cardiovascular disease
in the general population, it seems also worthwhile to
introduce similar prevention measures for a broader
public [8]. The question thus arises what would be the
best strategy: to target cardiovascular prevention to dia-
betes patients, to invest in prevention strategies intended
for the general population, or doing a mix of both?
Part of the answer to this question depends on the
relative efficiency of prevention in the general popula-
tion versus prevention targeting the high risk group of
diabetes patients. Numbers needed to treat are lower in
diabetes patients, but intervention costs and effective-
ness may differ.
Economic evaluations for a range of lifestyle and drug
interventions targeting diabetes patients,[9,10] or the
general population [11-15] have been published in recent
years. Evaluations of drug interventions dominate, but
smoking cessation and overweight reduction have also
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been evaluated frequently. The majority of these evalua-
tions applied some form of modelling to extrapolate from
the short term effects on intermediate outcomes such as
quitting smoking, weight reduction and lowering choles-
terol levels to the outcome of interest: long term health
in terms of mortality and quality of life. Trials with a fol-
low-up long enough to directly measure these outcomes
are rare, with the notable exception of the UKPDS [16].
Modelling has the added advantage that several sources
may be combined to provide a consistent picture of the
best available evidence [17].
However, comparing the outcomes of single evalua-
tions is difficult, among others since they were performed
in different countries [18,19]. Furthermore, not all eva-
luations included all relevant effects of the interventions.
Comparability is importantly increased when all interven-
tions are evaluated with the same model in the same set-
ting. Therefore, in this paper, we translated evidence for
all interventions to a single setting (that of the Dutch
healthcare system) and evaluated them using the same
model. This model was developed to capture all relevant
health effects of the types of prevention that were evalu-
ated, that is, not only effects on cardiovascular diseases,
but also those on other chronic diseases that show
increased risks for the risk factors targeted by the preven-
tive interventions. Furthermore, effects of prevention on
delaying mortality leading to diseases and costs of care in
life years gained were also taken into account [20,21].
This improved the comparability of the outcomes and
allowed to analyze the full trade-off between different tar-
get groups for prevention.
We show that such a comparison, however, cannot be
restricted to cost-effectiveness ratios. While informative,
it is clear that a prevention program for the general
population with a potential reach of 300,000 people will
be valued differently from a program fit for a selective
patient group consisting of 30,000 people. In other
words, program sizes matter [22].
Mathematical programming models for resource alloca-
tion combine the results of cost effectiveness analysis with
epidemiological and demographic data, as well as data on
program scale to find the optimal allocation of resources
over programs. Compared to a cost-effectiveness analysis,
the strength of a mathematical programming approach is
that program sizes and hence budgetary impact are taken
into account. The resulting choices of interventions are
different from those guided by cost-effectiveness only.
The approach furthermore allows analyzing the effect
of different objectives and constraints, for instance on
indivisible programs or equity [23,24]. Resource alloca-
tion models for diabetes or its prevention have been
undertaken previously [23,25,26]. These studies focused
on either primary prevention in the non diabetes popula-
tion or on prevention of complications for diabetes
patients separately. In contrast, the current study aimed
to compare both, and used resource allocation modelling
to address choices between both types of prevention,
considering a range of prevention programs and evaluat-
ing them using a model that accounts for the full effects
on health and costs of care.
The rest of the paper is structured as follows: first our
methods are set out, paying attention to our general
approach, the input data that were needed to populate the
model as well as the resource allocation model. Second,
results are presented in terms of total costs and health
benefits that may be obtained from the optimal allocation
of a given budget. Finally we discuss the results and their
policy implications.
Methods
General approach
To analyze the trade-off between four types of interven-
tions for the general population and in diabetes patients,
the following steps were taken. First, effects of the inter-
ventions on intermediate outcomes and intervention costs
were estimated. Second, modelling was applied to find
long term health effects and effects on healthcare costs,
using the same model for all interventions. Third, capacity
constraints and demand restrictions that may apply to the
interventions were assessed. Fourth, the long term costs
and effects were fed into a mathematical programming
model, combining them with information on constraints
and on population sizes to find optimal allocations for a
range of healthcare budgets.
Input data
Details and results of the first two steps have been pub-
lished for all interventions concerned in separate publica-
tions [27-32]. In short, first interventions were selected
based on the available evidence on effectiveness from sys-
tematic reviews and their relevance for the Dutch setting.
For these interventions effects of the interventions on
intermediate outcomes were estimated based on systematic
reviews, while intervention costs were calculated using bot-
tom up estimates of resource use and unit costs (Table 1).
Cost data are expressed in euro at price levels 2007.
The interventions in the general population are in prin-
ciple also available for people with diabetes. However, it
was assumed that the diabetes specific interventions get
priority in case of overlap of target groups. Costs for the
medication interventions specific for diabetes patients may
differ from similar interventions in the general population,
the main reason being different brands of medications
typically used and cost sharing with other diabetes control
consults. Effects and costs of interventions were corrected
for relapse and non-adherence. For smoking, relapse was
extensively modelled [33], while for overweight and activ-
ity, the effect of relapse was included in the final estimate
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of effectiveness [29,31]. For cholesterol lowering drugs and
blood pressure control medication, a correction for non-
adherence was done for those that would cease medication
use within two years by excluding health gains and drug
related costs after these two years [30,32].
Simulation model
The RIVM Chronic Disease Model (CDM) and its dia-
betes module were applied to compute the long term
effects of the interventions. The CDM is a Markov-type
simulation model,[20] and comprises epidemiological
data quantifying associations between multiple risk fac-
tors and chronic diseases among which cardiovascular
diseases and cancers. The CDM diabetes module simu-
lates the Dutch diabetes population [31]. The CDM has
been used among others to evaluate long-term outcomes
for diabetes prevention and treatment [29-31].
Current practice in the Netherlands served as a bench-
mark case, so that costs and effects are to be interpreted
as additional values compared to current practice. Net
cumulative gains in (quality adjusted) life expectancy and
net effects on the present value of health care costs were
estimated over a lifetime horizon. Costs and effects were
tracked until the last person of the cohort had died, for 3
age groups, 20-44 years, 45-64 years and 65 years and
older. Outcomes in future years were discounted at the
rates prescribed by the current Dutch guidelines for
pharmacoeconomic evaluations (4% and 1.5% annually
for health effects and costs respectively.) Total costs per
QALY for all 12 interventions, for three age categories,
for the intervention compared to usual care were esti-
mated (cf Table 1).
Constraints
In a third step, capacity and demand constraints were
added. For each age group and risk factor, the total num-
ber of persons receiving an intervention cannot be more
than the total size of the target population. For instance,
it is impossible to offer more smoking cessation support
courses for 65 and over than the number of smokers at
that ages. This results in a set of restrictions that were
added to the basic optimization model. Their values were
specified for the three age categories in Table S1 (Addi-
tional file 1) and were derived from information about
Table 1 Short term costs and effects of interventions (price level 2007)
Intervention Effectiveness* Annual costs per participant†
General population
Minimal cessation counseling by GP 28 €30
Intensive smoking cessation counseling plus pharmacotherapy 68 €420
Minimal lifestyle intervention, community intervention (Hartslag Limburg‡) Activity: 0-1
Overweight: 5-8
€6
Intensive lifestyle intervention for persons with extreme overweight (SLIM§) Activity: 1-6
Overweight: 18.
€700
Medication to reduce blood pressure for persons with SBP > 140 390 €1200-€280**
Statins for persons with total cholesterol > 6.5 470 €1500-€3700**
Diabetes patients
Minimal cessation counseling by GP 28 €30
Intensive smoking cessation counseling plus pharmacotherapy 68 €420
Minimal lifestyle intervention (X-PERT††) Activity: 50-90
Overweight: 35
€120
Intensive lifestyle intervention (LookAHEAD‡‡) Overweight: 140 €500
Medication to reduce blood pressure for persons with SBP > 140§§ 390 €1000-€3300**
Statins for al diabetes patients*** 470 €1100-€3800 **
* Short term effects expressed as the number of additional persons per 1000 participants that quit smoking, loose weight, increase activity, or continue lifelong
medication. Only continuous drug use was assumed to lead to effects on disease risks, the latter were different for the general population and diabetes patients
and for age and baseline risk [30,32]. Long term effects were age dependent and computed using the RIVM-Chronic Disease Model.
† Intervention costs only. Effects on costs of care were age dependent and computed in the RIVM-Chronic Disease Model. Earlier publications provide more
details on the intervention cost estimates [27-32]. All estimates were adjusted to price level 2007 using consumer price indices.
‡ Ronkers et al. [34]
§ Mensink et al. [35]
** Costs of lifetime medication use and consults were age dependent.
†† Deakin et al. [36]
‡‡ Pi-Sunyer et al. [37]
§§ Effects given are the number of persons that continue lifetime medication. Effects of medication on disease risks were based on a meta-analysis [38]. For full
details see the RIVM report by Jacobs-van der Bruggen et al. 2007 (available at http://www.rivm.nl/bibliotheek/rapporten/260801004.pdf).
*** Effects given are the number of persons that continue lifetime medication. Effects of medication on disease risks were based on a meta-analysis [6]. For full
details see Jacobs-van der Bruggen et al. 2008 [30] and the RIVM report mentioned above.
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lifestyle in the Dutch (diabetes) population and availabil-
ity of treatments. Furthermore, for each intervention,
constraints were added to reflect that the total number of
participants over all age groups for each intervention was
limited by professional capacity. These restrictions will
be referred to as capacity constraints (see Additional
file 1, Table S1).
Optimization model
The optimization model used in current application may
now be formally written as follows.
(1) Maxpja
∑
j
∑
a
pjaqja subject to
(2)
∑
j
∑
a
pjacja ≤ b and b given.
(3)
∑
a
pja ≤ capj , for all j,
(4) 0 ≤ pja ≤ demja, for all j, for all a
With:
j Index for programs, j = 1,...12.
a Index for age, a = 1,..3 age groups distinguished
pja Number of people of age a receiving program j
b Total available budget (Net present value over
entire time horizon)
q ja Health effects per participant of program j for
people of age a (Net present value)
c ja Costs of program j per participant of age a (Net
present value)
demja Demand restrictions for program j and age
group a
capj Capacity constraints for program j
The simulation model provided estimates for the
health effects and costs per participant (q ja and c ja).
These were combined with relevant constraints to form
the resource allocation model, which was then solved
using the linear programming features of Mathematica.
(routine LinearProgramming)
Constraints for demand were assumed to be age group
specific, while capacity constraints were given for each
program over all age groups together.
Sensitivity analyses
The standard model was analyzed for a range of different
budgets, to find optimal combinations of total health and
total costs. Then, we removed the capacity constraints to
estimate their effect in a second analysis. Finally, sensitiv-
ity analyses investigated the robustness of the results for
different discount rates and time horizons.
Results
Cost-effectiveness ratios
Table 2 shows the interventions in the different age
categories ordered at increasing costs per QALY. For
most interventions, long term cost effectiveness was
lowest for the lowest age category, since at this age the
full effects of prevention could be included, before any
harm has been done. The exceptions were statins for
diabetes patients and blood pressure treatment for the
general population, reflecting that for this age category
too many unnecessary cases will be treated lifelong.
Based on these cost-effectiveness ratios only, low bud-
gets would seem to be spent primarily in diabetes patients:
In total 17 interventions had average cost-effectiveness
below €10,000 per QALY, and 11 of these were for dia-
betes patients. The 13 interventions costing between
€10,000 and €20,000 per QALY consisted of 5 diabetes
interventions and 8 interventions for the general popula-
tion. Finally, 6 interventions cost more than €20,000 per
QALY, and 4 of these were for the general population.
That is, interventions in the diabetes population were
mostly more cost-effective than in the general population
reflecting the effect of targeting to a high risk group. How-
ever, low intensity overweight and activity programs were
more cost-effective in the general population. This may be
explained from the relatively higher effectiveness of the
general population program. It cost much less and had
relatively a better effect. A possible explanation is that dia-
betes patients already experienced serious problems from
being overweight and yet did not succeed in loosing
weight, so they may need more intensive programs to suc-
cessfully loose weight.
Proportion of money spent in the general population
Table 3 shows optimal allocations and incremental cost-
effectiveness ratios for a range of total budgets. At most
these 12 interventions offered the possibility to gain an
additional 560,000 QALY, for about €640 per capita in
additional costs over the entire time horizon. Table 3
also presents the percentages of health gains and money
obtained from prevention in the general population. At
low budgets, all money was optimally allocated towards
this type of interventions, especially smoking cessation
and overweight reduction. Moderately high budgets
however (that is, more than €9 per capita, or below
€100 per capita), were spent mostly on prevention in
diabetes. The optimal set now additionally included
increased use of statins and medication for blood pres-
sure in diabetes patients as well as intensive overweight
reduction. Finally, for very high budgets, above €100 per
capital, additional medication for the general population
was added. The majority of budgets were again allocated
to prevention in the general population. Hence, the opti-
mal distribution of money between interventions in dia-
betes patients or the general population depended on
available budgets.
From Table 2 ranking on cost-effectiveness ratios
only seemed to indicate that targeted prevention
was more efficient in general. However, the optimal
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allocations (Table 3) showed that due to varying sizes
of target populations and capacity constraints no gen-
eral a priori priority for either type of prevention
existed and it depended on the size of the budget, as
well as available interventions, whether most resources
were spent in universal prevention or in targeted pre-
vention or both.
Effects of supply limits
Running the optimization model without the capacity
constraints on the maximal supply of each intervention
resulted in almost a doubling of maximal potential
health gains from 0.56 million QALY to 0.96 million
QALY. Table 4 below gives the outcomes of a model
without capacity limits, for the same range of budgets as
Table 2 Costs per QALY compared to care as usual
Average costs per QALY (euro) Age category Target population Intervention
(Short name)
1400 20-44 General population Minimal cessation counseling by GP (S1)
1500 20-44 Diabetes patients Minimal cessation counseling by GP (Sd1)
2700 45-64 Diabetes patients Minimal cessation counseling by GP (Sd2)
2900 45-64 General population Minimal cessation counseling by GP (S2)
3000 20-44 General population Hartslag Limburg (HL1)
5400 45-64 General population Hartslag Limburg (HL2)
5800 20-44 Diabetes patients LookAHEAD (LA1)
5900 20-44 Diabetes patients X-PERT (XP1)
6400 20-44 Diabetes patients Intensive smoking cessation counseling plus pharmacotherapy((ISd1)
6700 20-44 General population Intensive smoking cessation counseling plus pharmacotherapy (IS1)
6800 20-44 Diabetes patients Medication to reduce blood pressure for persons with
SBP > 140 (BPd1)
7400 45-64 Diabetes patients X-PERT (XP2)
7800 45-64 Diabetes patients Medication to reduce blood pressure for persons with
SBP > 140 (BPd2)
8000 65+ Diabetes patients Minimal cessation counseling by GP (Sd3)
8600 45-64 General population Intensive smoking cessation counseling plus pharmacotherapy (IS2)
9200 45-64 Diabetes patients Intensive smoking cessation counseling plus pharmacotherapy (ISd2)
9800 45-64 Diabetes patients Statins for all diabetes patients (Std2)
10100 45-64 Diabetes patients LookAHEAD (LA2)
10500 65+ General population Minimal cessation counseling by GP (S3)
10900 45-64 General population Medication to reduce blood pressure for persons with SBP > 140 (BP2)
11000 20-44 Diabetes patients Statins for all diabetes patients (Std1)
11200 20-44 General population Medication to reduce blood pressure for persons with SBP > 140 (BP1)
12900 65+ Diabetes patients Medication to reduce blood pressure for persons with SBP > 140 (BPd3)
16100 65+ General population Hartslag Limburg (HL3)
16600 65+ General population Medication to reduce blood pressure for persons with SBP > 140 (BP3)
16600 65+ Diabetes patients Statins for all diabetes patients (Std3)
18100 20-44 General population Statins for persons with total cholesterol > 6.5 (St1)
18500 45-64 General population Statins for persons with total cholesterol > 6.5 (St2)
19700 65+ Diabetes patients X-PERT (XP3)
19900 20-44 General population SLIM (SL1)
27300 45-64 General population SLIM (SL2)
28100 65+ General population Statins for persons with total cholesterol > 6.5 (St3)
32300 65+ Diabetes patients Intensive smoking cessation counseling plus pharmacotherapy (ISd3)
33200 65+ Diabetes patients LookAHEAD (LA3)
35500 65+ General population Intensive counseling plus pharmacotherapy (IS3)
59600 65+ General population SLIM (SL3)
For the interventions in each age category ordered at worsening cost-effectiveness. (Net present values over a lifetime horizon. Discount rates 4% for costs and
1.5% for QALYs, price level 2007.).
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Table 3 Optimization results for different budgets
Budget
(€ *10^6)
Spent in general population (%) Total health gains (QALY*1000) Gained in general population (%) Incremental costs per QALY Changes in interventions chosen i
1 100 700 100 €1,400 + S1
10 100 6,950 100 €1,400 NAii
100 89 29,400 90 €6,700 + IS1, Sd1, Sd2, HL1,
HL2, XP1
250 65 50,400 74 €7,400 + XP2, BPd1, BPd2
500 32 78,100 47 €9,800 + Sd3, Std2
750 24 103,000 37 €10,900 + ISd1, LA2, BP2
- Sd1
1,000 43 126,000 49 €10,900 NA
2500 77 264,000 76 €10,900 NA
5,000 83 440,000 81 €18,100 + ISd2, BP1, BPd3, St1
- Sd2
7,253 88 561,000 84 €49,300 + ISd3, SL1, LA3, St2, Std1
- Sd3
Maximal health gains and incremental costs per QALY for a range of different budgets. Net present values over a lifetime horizon. Discount rates 4% for costs and 1.5% for QALYs, price level 2007. Interventions
added as compared to the set chosen for the budget in the previous row are indicated by +, interventions removed are indicated by -.
i A list of the interventions and their abbreviations is given in Table 2.
ii That is, more money was spent on the same set of interventions as in the previous row
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Table 4 Optimization results in model without capacity constraints
Budget (€ *10^6) Spent in general population (%) Total health gains (QALY *1000) Gained in general population (%) Incremental costs per QALY
1 100 700 100 €1,460
10 100 6,950 100 €1,460
100 96 49,600 96 €3,040
250 96 78,000 96 €7,230
500 74 113,000 84 €8,510
750 73 142,000 81 €10,900
1000 55 168,000 68 €10,900
2500 70 309,000 73 €13,700
5000 77 516,000 78 €20,000
7250 78 651,000 78 €20,800
10,000 84 801,000 82 €21,700
Maximal budget: 13,587 87 958,000 84 €426,000
Maximal health gains and incremental costs per QALY for a range of different budgets. Model without capacity constraints. (Net present values over a lifetime horizon. Discounted rates 4% for costs and 1.5% for
QALYs, price level 2007.)
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in Table 3. The maximal total budget to be spent on the
12 interventions was of course higher and amounted to
circa €1200 per capita.
Figure 1 shows optimal combinations of budgets and
total health effects, that is, the choices that obtain most
health for a given budget. The steepness of the different
line segments represents the incremental cost-effective-
ness ratios. In other words, they reflect the additional
costs that must be paid for one additional QALY, if the
extra money is spent in the most efficient way. At corner
points, one or more constraints force a change in the set
of programs chosen. The two lines represent the model
with and without capacity constraints and illustrate the
effects of these constraints. For any given budget, less
health can be obtained, while the upper limit to health
benefits is substantially reduced in case of capacity
constraints.
Comparison of Tables 3 and 4 shows that the capacity
constraints reduced the percentage of the budget spent
in the general population. This indicates that capacity
constraints were more limiting for interventions in the
general population than for interventions targeted at
diabetes patients.
Sensitivity analyses
Sensitivity analyses showed that the time horizon mat-
tered, because at shorter time horizons, neither the full
costs in life years gained, nor the full health effects could
be realized. Thus, maximal total costs and maximal total
health effects were smaller. Figure 2 shows the efficiency
frontiers for time horizons of 25, and 50 years, compared
to the lifetime horizon chosen in the main analysis. Too
short time horizons caused relevant effects to be left out
of the analysis.
Furthermore, the outcomes were sensitive to the rate of
discount, as is usually the case in economic evaluations of
prevention, with health outcomes occurring far in the
future and intervention costs having to be paid immedi-
ately. The base case discounted health effects at 1.5% and
costs at 4%, which is the current Dutch standard (cf
http://www.cvz.nl). For discount rates at 4% for both
health and costs, the efficiency frontier moved inward,
since the net present value of health effects decreased.
For discount rates of 0% on both health and costs, it
moved outward. Increasing the difference in discounting
between costs and health effects, with health effects dis-
counted at 0%, rather than 1.5%, moved the efficiency
frontier outward.
Discussion
The current study used a resource allocation model to
analyze prevention of diabetes and its complications in
the Netherlands. Optimal resource allocations were com-
puted over a set of 12 interventions aiming to reduce the
risk for diabetes and/or cardiovascular disease, either in
the general population or in diabetes patients. While for
small and high budgets the majority of money would go
to interventions in the general population, moderately
high budgets were mostly spent in diabetes patients.
Strengths of the resource allocation approach were that
it was relatively straightforward to account for con-
straints and analyze their effects. These constraints are
for instance due to limited capacity to provide interven-
tions. Removing constraints on intervention supply
increased maximal additional expenditure from €640 to
€1200 per capita and almost doubled maximal potential
health gains. The constraints were more limiting for pre-
vention in the general population than for interventions
in diabetes patients. This makes sense, since the group of
diabetes patients is much smaller.
The model used to evaluate long term health effects
took into account limited effectiveness and adherence,
competing risks, and relapse. Hence, the estimates took
care not to overestimate health effects. Our special atten-
tion went to the health care costs to be included in the
budget allocation model. In this study, costs consisted of
intervention costs plus the full long term effects of preven-
tion on health care costs. Alternatively only intervention
Figure 1 Cost effectiveness efficiency frontiers. model with
capacity constraints (dark, solid line). model without capacity
constraints (light, dashed line).
Figure 2 Effect of different time horizons, model with capacity
constraints. 25 years (light dotted line). 50 years (grey dashed line).
lifetime horizon (black solid line, reference case).
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costs could be included in the budgets. While the latter
may result in numbers that are closer to common sense
ideas about the sizes of the budgets at stake, it is inconsis-
tent from a long term perspective [21]. Changing to short
term budgets increased the variability of choices between
prevention in the general population and targeted preven-
tion (results not shown).
Another distinctive feature of our modeling exercise is
that we accounted for quality of life decreases with
advancing age. This is important, since obviously most
of the life years gained occur at advanced ages.
While the current results were specific for the Nether-
lands, the general approach could be applied to any set-
ting. This would require either an existing disease model
comparable to the RIVM chronic disease model, or a
transfer of this model to the appropriate setting, replacing
prevalence, incidence and mortality parameters by setting
specific estimates. Furthermore, the cost estimates of the
interventions, as well as the estimates of capacities and
further constraints should be adjusted if they were
expected to differ from the Dutch estimates.
Similar recent applications of resource allocation in dia-
betes and in obesity prevention have appeared in the UK
and in Australia [23,26]. The study by Segal focused on
prevention in the general population, especially different
types of overweight control. Indirect medical costs were
not included and costs were computed per life year gained,
ignoring effects on quality of life. The study by Earnshaw
only considered prevention in the diabetes population. In
contrast, the current study also included interventions in
the general population and therefore allowed to explore
the trade off between both types of prevention. Further-
more, Earnshaw used a full experimental design to directly
compute results for any combination of prevention inter-
ventions. In the current paper, a simpler approach was
applied with only single intervention policies modeled,
assuming additive health effects. Third, Earnshaw focused
on intervention costs only, which implies the implicit
assumption that health care cost effects would be the
same for all interventions. That is clearly not the case for
interventions on overweight versus smoking cessation or
statin treatment. Finally, they did not incorporate age
effects on quality of life, which is important if trade-offs
are made between age groups.
While a number of diabetes models have been pub-
lished in recent years, [39] for the current application we
preferred to use the RIVM Chronic Disease Model
(CDM). While this model maybe less well known, all
parameters estimates are accessible and the general
structure of the CDM as well as relevant applications
have been published in peer reviewed journals [20,27-33].
The most important advantage of this model for our cur-
rent purpose was that it allows evaluating interventions
in the general population and in diabetes patients using
the same model.
Some assumptions in our current study require further
discussion. First of all, combinations of interventions
were assumed to have no specific interaction effects, that
is, the health gains in terms of life years and QALYs
gained were assumed additive. This same assumption
was made for instance in the global burden of disease
study [40]. It probably implies an overestimation of total
health effects if persons receive more than one interven-
tion. This assumption is a bit more problematic in the
diabetes population than in the general population. Thus
the effects of the diabetes interventions may have been
overestimated as compared to interventions in the gen-
eral population, implying that the optimal shares of
money spent in the general population might be higher
than our results indicated. Second, another assumption
applied in the current paper was the possibility to offer
interventions to a population of variable size, by varying
the budget spent on each intervention. Some resource
allocation models pay specific attention to the conse-
quences of having indivisible interventions of fixed sizes
[41]. The optimization problem then changes into a so
called integer programming problem. The question
whether program size is variable or not depends on the
interventions at stake. For the current interventions, it
was rather easy to vary sizes by having more or less
money available for them, because most of them were
supply driven and addressed people that are not yet
acutely ill. For curative interventions, varying program
size may be more problematic, since it would imply that
some actual patients would receive improper treatment.
While we did provide sensitivity analyses for the
effects of discount rates, time horizon and budgetary
constraints, a more extensive uncertainty analysis would
improve insight into the robustness of our outcomes.
This requires the use of stochastic programming techni-
ques and we would like to address this issue in future
research.
A further advantage of the resource allocation
approach is that once the model has been formulated, it
is easy to vary constraints and objectives, for instance on
indivisible programs or equity [23,24]. The current
results on capacity constraints might help to focus efforts
to extend prevention capacity to those areas where it
would be most worthwhile, using the shadow prices of
the constraints.
A drawback of resource allocation models may be seen
in their data greediness. However, most of these data
would be needed for careful priority setting anyway. The
only additional requirement for a budget allocation model
is that all data used are consistent and can be sensibly
combined in the same model. Therefore, using a resource
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allocation model forces to seek for consistent, well com-
parable data, and that maybe considered an advantage
rather than a drawback [17].
Conclusions
Resource allocation models may help health care decision
makers to integrate information about the costs, sizes,
and health effects of sets of programs. Our diabetes appli-
cation had U-shaped results: prevention in the general
population was the best way to retain health benefits for
low and high budgets, while moderate budgets would
mostly be spent on prevention in diabetes patients.
Targeted prevention in diagnosed patients was therefore
not a priori more or less efficient than prevention in the
general population. The application also showed that an
additional 560 thousand QALYs may be gained by cur-
rently available interventions even when accounting for
existing capacity and demand limits.
Additional material
Additional file 1: Table S1. Table with information about constraints on
the demand and capacity of interventions.
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